Pfizer Gets CDSCO Panel Nod To Study Anticancer Drug Disitamab vedotin
New Delhi: Citing that more geographically distributed government sites shall be included in the study, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has recommended the drug major Pfizer for conducting phase 3 clinical study of the anti-cancer drug Disitamab vedotin.
The expert panel further suggested that the principal investigator (PI) shall be a medical oncologist only.
This came after the drug maker Pfizer presented phase 3 clinical study protocol no. C5731001 amendment 03 dated 03-December-2024.
Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancer.
Disitamab vedotin, an antibody-drug conjugate (ADC), targets HER2-expressing cancer cells. It works by binding to HER2, being internalized, and releasing the cytotoxic payload MMAE, which inhibits tubulin polymerization, leading to cell death and potentially bystander killing.
At the recent SEC meeting for Oncology held on 11th March 2025, the expert panel reviewed the phase 3 clinical study protocol no. C5731001 amendment 03 dated 03-December-2024.
After detailed deliberation, the committee recommended the grant of permission to conduct the trial as presented by the firm with the following condition:
1. More geographically distributed government sites shall be included in the study.
2. PI shall be a medical oncologist only.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.